| Name | Title | Contact Details |
|---|
Maxygen, Inc. (Maxygen) is a biotechnology company engaged in the discovery and development of improved protein pharmaceuticals for the treatment of disease and serious medical conditions.
Intrinsic Therapeutics, Inc is a MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
StemCells, Inc., a biopharmaceutical company, engages in the research, development, and commercialization of cell-based therapeutics and tools for use in stem cell-based research and drug discovery primarily in the United States. Its lead therapeutic product candidate, HuCNS-SC cells (purified human neural stem cells), is in development as a potential treatment for a range of central nervous system disorders. The company has conducted a Phase I clinical trial in Pelizaeus-Merzbacher disease, a fatal myelination disorder in children. It is also conducting a Phase I/II clinical trial in chronic spinal cord injury; and has initiated a Phase I/II clinical trial in dry age-related macular degeneration, as well as is pursuing preclinical studies in Alzheimer’s disease. In addition, the company markets a rage of proprietary cell culture products, research grade human cells, and antibody reagents under the SC Proven brand. The proprietary cell culture products include iSTEM, GS1-R, GS2-M, RHB-A, RHB-Basal, NDiff227, NDiff N2, and NDiff N27 supplements, as well as HEScGRO and ESGRO Complete; and antibody reagents comprise STEM24, STEM101, STEM121, and STEM123, which can be used for cell detection, isolation, and characterization. Further, StemCells is involved in developing and commercializing applications of its technologies to enable stem cell-based research. The company sells its tools and technologies products to researchers at academic institutions, pharmaceutical and biotechnology companies, and government laboratories. StemCells, Inc. was founded in 1988 and is headquartered in Newark, California.
Bloomington Hospital is dedicated to serving the entire community. We recognize that some of our patients may need assistance when communicating with physicians and staff. A number of services are available at no cost to patients by calling the Hospital
Cohera Medical, Inc. is a rapidly growing medical device company actively developing surgical adhesives and sealants. TissuGlu Surgical Adhesive, the first synthetic adhesive approved for internal use, is an easily applied biocompatible, resorbable adhesive that requires no mixing or thawing. Indicated for the approximation of tissue layers where subcutaneous dead space exists between tissue planes in abdominoplasty, TissuGlu Surgical Adhesive has been shown to eliminate the need for postoperative surgical drains in most abdominoplasty procedures.